Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Feb 2

PMID 23372693

Citations 55

Authors

Susanne Strohmaier

Michael Edlinger

Jonas Manjer

Tanja Stocks

Tone Bjorge

Wegene Borena

Christel Haggstrom

Anders Engeland

Gabriele Nagel

Martin Almquist

Randi Selmer

Steinar Tretli

Hans Concin

Goran Hallmans

Hakan Jonsson

Par Stattin

Hanno Ulmer

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the association between total serum cholesterol (TSC) and cancer incidence in the Metabolic syndrome and Cancer project (Me-Can).

Methods: Me-Can consists of seven cohorts from Norway, Austria, and Sweden including 289,273 male and 288,057 female participants prospectively followed up for cancer incidence (n = 38,978) with a mean follow-up of 11.7 years. Cox regression models with age as the underlying time metric were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) for quintiles of cholesterol levels and per 1 mmol/l, adjusting for age at first measurement, body mass index (BMI), and smoking status. Estimates were corrected for regression dilution bias. Furthermore, we performed lag time analyses, excluding different times of follow-up, in order to check for reverse causation.

Results: In men, compared with the 1st quintile, TSC concentrations in the 5th quintile were borderline significantly associated with decreasing risk of total cancer (HR = 0.94; 95%CI: 0.88, 1.00). Significant inverse associations were observed for cancers of the liver/intrahepatic bile duct (HR = 0.14; 95%CI: 0.07, 0.29), pancreas cancer (HR = 0.52, 95% CI: 0.33, 0.81), non-melanoma of skin (HR = 0.67; 95%CI: 0.46, 0.95), and cancers of the lymph-/hematopoietic tissue (HR = 0.68, 95%CI: 0.54, 0.87). In women, hazard ratios for the 5th quintile were associated with decreasing risk of total cancer (HR = 0.86, 95%CI: 0.79, 0.93) and for cancers of the gallbladder (HR = 0.23, 95%CI: 0.08, 0.62), breast (HR = 0.70, 95%CI: 0.61, 0.81), melanoma of skin (HR = 0.61, 95%CI: 0.42, 0.88), and cancers of the lymph-/hematopoietic tissue (HR = 0.61, 95%CI: 0.44, 0.83).

Conclusion: TSC was negatively associated with risk of cancer overall in females and risk of cancer at several sites in both males and females. In lag time analyses some associations persisted, suggesting that for these cancer sites reverse causation did not apply.

Citing Articles

Lipids, apolipoproteins, carbohydrates, and risk of hematological malignancies.

Liu Q, Wei D, Hammar N, Yang Y, Feychting M, Zhang Z Eur J Epidemiol. 2025; .

PMID: 40038140 DOI: 10.1007/s10654-025-01207-y.

Serum Lipid Biomarkers and the Risk of Gastrointestinal Cancers in a Chinese Population: The Kailuan Prospective Study.

Xiao Y, Du X, Wang T, Liu D, You H, Wang H Cancer Med. 2025; 14(3):e70654.

PMID: 39912426 PMC: 11799922. DOI: 10.1002/cam4.70654.

The role of cholesterol metabolism in lung cancer.

Xiu W, Liu X, Hu K, Zhang Q, Shi H Oncol Res. 2024; 32(10):1613-1621.

PMID: 39308527 PMC: 11413819. DOI: 10.32604/or.2024.047933.

The relationship between lipoproteins and the risk of esophageal cancer: a Mendelian randomization study.

Cui J, Zhang R, Li L Front Nutr. 2024; 11:1432289.

PMID: 39246397 PMC: 11377315. DOI: 10.3389/fnut.2024.1432289.

Investigating the Relationship between Body Mass Index, Cholesterol, and Cancer in United States Adults: A Cross-Sectional Study.

Martinovic A, Axon D Diseases. 2024; 12(6).

PMID: 38920552 PMC: 11202576. DOI: 10.3390/diseases12060120.

References

Lim U, Gayles T, Katki H, Stolzenberg-Solomon R, Weinstein S, Pietinen P . Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. Cancer Res. 2007; 67(11):5569-74. DOI: 10.1158/0008-5472.CAN-07-0212. View

Wood A, White I, Thompson S, Lewington S, Danesh J . Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol. 2006; 35(6):1570-8. DOI: 10.1093/ije/dyl233. View

Trompet S, Jukema J, Katan M, Blauw G, Sattar N, Buckley B . Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol. 2009; 170(11):1415-21. DOI: 10.1093/aje/kwp294. View

Kreger B, Anderson K, Schatzkin A, Splansky G . Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer. 1992; 70(5):1038-43. DOI: 10.1002/1097-0142(19920901)70:5<1038::aid-cncr2820700505>3.0.co;2-m. View

Morris D, Borhani N, Fitzsimons E, Hardy R, Hawkins C, Kraus J . Serum cholesterol and cancer in the Hypertension Detection and Follow-up Program. Cancer. 1983; 52(9):1754-9. DOI: 10.1002/1097-0142(19831101)52:9<1754::aid-cncr2820520933>3.0.co;2-j. View

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

Ahn J, Lim U, Weinstein S, Schatzkin A, Hayes R, Virtamo J . Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18(11):2814-21. PMC: 3534759. DOI: 10.1158/1055-9965.EPI-08-1248. View

Fagherazzi G, Fabre A, Boutron-Ruault M, Clavel-Chapelon F . Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Eur J Cancer Prev. 2010; 19(2):120-5. DOI: 10.1097/CEJ.0b013e3283354918. View

Borena W, Strohmaier S, Lukanova A, Bjorge T, Lindkvist B, Hallmans G . Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer. 2011; 131(1):193-200. DOI: 10.1002/ijc.26338. View

10.

Clarke R, Lewington S, Youngman L, Sherliker P, Peto R, Collins R . Underestimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. Eur Heart J. 2002; 23(4):286-93. DOI: 10.1053/euhj.2001.2781. View

11.

Kitahara C, Berrington de Gonzalez A, Freedman N, Huxley R, Mok Y, Jee S . Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011; 29(12):1592-8. PMC: 3082977. DOI: 10.1200/JCO.2010.31.5200. View

12.

Strasak A, Pfeiffer R, Brant L, Rapp K, Hilbe W, Oberaigner W . Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. Ann Oncol. 2009; 20(6):1113-20. PMC: 2685450. DOI: 10.1093/annonc/mdn736. View

13.

Stocks T, Borena W, Strohmaier S, Bjorge T, Manjer J, Engeland A . Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). Int J Epidemiol. 2009; 39(3):660-7. PMC: 2878454. DOI: 10.1093/ije/dyp186. View

14.

Salonen J . Risk of cancer and death in relation to serum cholesterol. A longitudinal study in an eastern Finnish population with high overall cholesterol level. Am J Epidemiol. 1982; 116(4):622-30. DOI: 10.1093/oxfordjournals.aje.a113445. View

15.

Johansen D, Stocks T, Jonsson H, Lindkvist B, Bjorge T, Concin H . Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev. 2010; 19(9):2307-17. DOI: 10.1158/1055-9965.EPI-10-0234. View

16.

Cambien F, Ducimetiere P, Richard J . Total serum cholesterol and cancer mortality in a middle-aged male population. Am J Epidemiol. 1980; 112(3):388-94. DOI: 10.1093/oxfordjournals.aje.a113004. View

17.

Schatzkin A, Hoover R, Taylor P, Ziegler R, Carter C, Albanes D . Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res. 1988; 48(2):452-8. View

18.

Whitlock G, Clark T, Hoorn S, Rodgers A, Jackson R, Norton R . Random errors in the measurement of 10 cardiovascular risk factors. Eur J Epidemiol. 2002; 17(10):907-9. DOI: 10.1023/a:1016228410194. View

19.

Tornberg S, Holm L, Carstensen J, Eklund G . Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N Engl J Med. 1986; 315(26):1629-33. DOI: 10.1056/NEJM198612253152601. View

20.

Kark J, Smith A, HAMES C . Serum retinol and the inverse relationship between serum cholesterol and cancer. Br Med J (Clin Res Ed). 1982; 284(6310):152-4. PMC: 1495538. DOI: 10.1136/bmj.284.6310.152. View